SeenewsSeenews
Search
Seenews
AlertsSeenewsSeenews
Searchclose
TOPICS
arrow
COUNTRIES
arrow
INDUSTRY
arrow
Economy
arrow
Browse Economy
Mix and match your focus countries with our advanced search
Investments
arrow
Browse Investments
Mix and match your focus countries with our advanced search
Deals
arrow
Browse Deals
Mix and match your focus countries with our advanced search
Tech
arrow
Browse Tech
Mix and match your focus countries with our advanced search
Green
arrow
Browse Green
Mix and match your focus countries with our advanced search
0/5
You have 5 free articles left this month
You have 0/5 free articles
Sign up to get 5 more free articles this month
SIGN UP
arrow
LOGIN
arrow

N. Macedonia's Replek expects 24% sales revenue growth in 2024

Feb 23, 2024, 11:06:33 AMArticle by Dragana Petrushevska
share
February 23 (SeeNews) - North Macedonia's drug maker Replek [MSE:REPL] said on Friday it expects to boost its sales revenue 24% year-on-year to 1.9 billion denars ($33.4 million/30.8 million euro) in 2024.

N. Macedonia's Replek expects 24% sales revenue growth in 2024
Author: Brice Ambrosiak. Licence: Creative Commons

Sales revenue from abroad are expected to grow 17.1% on the year to 1.4 billion denars in 2024, while domestic sales are seen growing 47% to 488.8 million denars, Replek said in its 2024 financial plan filed with the Skopje bourse.

Replek's shares last traded at an average price of 98,591 denars on the Macedonian Stock Exchange (MSE) on Thursday, according to the latest available bourse data.

(1 euro = 61.60 denars)

Your complete guide to the emerging economies of Southeast Europe. From latest news to bespoke research – the big picture at the tip of your fingers.